Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy , Asthma & Immunology Annual Meeting

The US drugs giant Ionis Pharmaceuticals has announced further improvements in the treatment of patients with hereditary ageing (HAE) - a potentially best-in-class treatment for patients living with the condition. Scientists have revealed that the drug's potential to be the best in class prophylactic treatment.

Source: prnewswire.com
Published on 2023-02-21